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Probing the GnRH receptor agonist binding site identifies
methylated triptorelin as a new anti-proliferative agent
Kevin Morgan, Samuel P. Leighton, and Robert P. Millar
Medical Research Council Human Reproductive Sciences Unit, The Queens Medical Research
Institute, Edinburgh, Scotland EH16 4TJ, United Kingdom
Abstract
D-amino acid substitutions at glycine postion 6 in GnRH-I decapeptide can possess super-agonist
activity and enhanced in vivo pharmacokinetics. Agonists elicit growth-inhibition in tumorigenic
cells expressing the GnRH receptor above threshold levels. However, new agonists with modified
properties are required to improve the anti-proliferative range. Effects of residue substitutions and
methylations on tumourigenic HEK293[SCL60] and WPE-1-NB26-3 prostate cells expressing the
rat GnRH receptor were compared. Peptides were ranked according to receptor binding affinity,
induction of inositol phosphate production and cell growth-inhibition. Analogues possessing D-
Trp6 (including triptorelin), D-Leu6 (including leuprolide), D-Ala6, D-Lys6, or D-Arg6 exhibited
agonist and anti-proliferative activity. Residues His5 or His5,Trp7,Tyr8, corresponding to residues
found in GnRH-II, were tolerated, with retention of sub-nanomolar/low nanomolar binding
affinities and EC50s for receptor activation and IC50s for cell growth-inhibition. His5D-Arg6-
GnRH-I exhibited reduced binding affinity and potency, effective in the mid-nanomolar range.
However, all GnRH-II-like analogues were less potent than triptorelin. By comparison, three
methylated-Trp6 triptorelin variants showed differential binding, receptor activation and anti-
proliferation potency. Significantly, 5-Methyl-DL-Trp6-Triptorelin was equipotent to triptorelin.
Subsequent studies should determine whether pharmacologically enhanced derivatives of
triptorelin can be developed by further alkylations, without substitutions or cleavable cytotoxic
adducts, to improve the extent of growth-inhibition of tumour cells expressing the GnRH receptor.
Introduction
Gonadotropin releasing hormone (GnRH) agonists can elicit cancer cell growth inhibition
via activation of the GnRH receptor (Franklin et al. 2003). Cell growth-inhibition usually
occurs provided the receptor expression levels exceed a certain threshold at the cell surface
(Franklin et al. 2003; Morgan et al. 2008 and 2011) but the extent of growth inhibition may
be confounded by other factors including the particular organization or mutation of the
intracellular signaling pathways (Morgan et al. 2011). Consequently, there is a need to
develop new GnRH agonists that are able to improve experimental tumour eradication and
to impact upon cells expressing sub-threshold levels of the receptor; or to affect certain cell
types currently resistant to the anti-proliferative effects of GnRH receptor activation.
Different approaches to the development of GnRH agonists have been used in the past.
Historically, structure-function studies using synthetic peptide analogues of GnRH (Karten
& Rivier 1986) led to the identification of super-agonists containing D-amino acid
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substitutions (Coy et al. 1976). A D-amino acid residue at position 6, replacing glycine in
native GnRH-I (pyroGlu1,His2,Trp3,Ser4,Tyr5, Gly6,Leu7,Arg8, Pro9,Gly10-NH2) increases
receptor binding affinity and lowers the dose required to reach half-maximal receptor
activation (Excitatory Concentration, EC50) (Clayton & Catt 1980). The D-amino acid also
increases the resistance of synthetic peptides to enzymatic degradation by peptidases and
slows clearance in vivo, contributing to an increased pharmacokinetic half-life (Barron et al.
1982, Ezan et al. 1986, Redding & Schally 1981). A modified D-amino acid residue,
containing a benzene- or a di-cyclic aromatic (‘naphthyl’) moiety can be incorporated at
position 6, with the bulkiest side-chain reported being iso-butyl-[6-(3-(2-naphthyl)-D-
alanine)]-GnRH-I. This analogue was estimated to be slightly more potent than the D-Trp6-
GnRH-I super-agonist, triptorelin (Ho et al. 1984, Nestor et al. 1982 and 1984) in bioassays
available at that time (Clayton & Catt 1980, Loumaye et al. 1982). Subsequently, an
extended side-chain at position 6 was used to introduce cytotoxic GnRH conjugates such as
D-Lys6-doxorubicin (Janáky et al. 1992) and D-Lys6-curcumin (Aggarwal et al. 2011).
However, a drawback associated with cytotoxic GnRH conjugates is their cleavage by serum
enzymes prior to GnRH receptor-mediated cell targeting (Nagy et al. 2000).
An alternative drug development strategy would be to seek to improve the anti-proliferative
efficiency by developing new GnRH receptor agonists without the addition of cleavable
cytotoxic adducts. Several studies have investigated how GnRH-II
(pyroGlu1,His2,Trp3,Ser4, Hisr5, Gly6,Trp7,Tyr8, Pro9,Gly10-NH2) interacts with the type I
GnRH receptor (Lu et al. 2005, Millar et al. 2008, Pfleger et al. 2002 and 2008) and
suggested that GnRH-II-like ligands may elicit cancer cell growth inhibition more potently
than GnRH-I analogues (Lopez de Maturana et al. 2008).
In this study, we compared the properties of nine GnRH analogues possessing substitution
of specific residues or side-chain methylation. Screening was performed using two human
cell lines which stably express high levels of the rat GnRH receptor and which are
reproducibly growth inhibited following receptor activation (Morgan et al. 2008 and 2011).
Three analogues possessed a D-amino acid at position 6 (either D-Trp6, -Lys6 or -Arg6) and
a His residue at position 5. A further three analogues possessed an additional dual
substitution at positions 7 and 8, thus incorporating His5,Trp7,Tyr8 to generate GnRH-II-like
peptides. Finally, three methylated -DL-Trp6 GnRH-I peptides, modified by alkyl moiety
addition to the tryptophan side-chain benzene ring positions 4, 5 or 6, were compared to the
super-agonist triptorelin since previous studies of side-chain alkylation have only addressed
position Trp3 but not the critically important position 6 (Yabe et al. 1979, Deghenghi, 1997).
Interestingly, the GnRH-II residue substitution analogues were less potent than triptorelin
whilst one of the methylated triptorelin analogues exhibited high potency, indicating scope
for the generation of new triptorelin-based drugs which may possess improved
pharmacological or pharmaco-dynamic properties for tumour growth inhibition.
Materials and Methods
Reagents
HPLC purified synthetic peptides were purchased from Sigma, UK or were custom
synthesized by EZ Biolabs, USA or Eurogentech, Germany. GnRH analogues were selected
to enable examination of primary sequence differences between GnRH-I and GnRH-II.
Methylated triptorelin isoforms were synthesised using readily available methylated-DL-
tryptophan isomers.
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Cell culture
HEK293[SCL60] cells were maintained in DMEM with 10% fetal bovine serum containing
G418. All assays using these cells required plates coated with matrigel. WPE-1-NB26-3
cells were grown in keratinocyte medium supplemented with bovine pituitary extract and
recombinant human epidermal growth factor (Invitrogen kit, UK). Human prostate cancer
cell lines PC3, LNCaP and DU145 were grown in DMEM with 10% fetal bovine serum.
Whole cell binding assay
Cells were plated in 12-well or 24-well plates for the 125I-GnRH binding assay, using 125I-
labeled His5D-Tyr6GnRH-I as a tracer (Flanagan et al. 1998). The method has been
described previously (Morgan et al. 2008 and 2011). Peptide dilutions were prepared in
HEPES-DMEM containing 0.1% BSA. Specific binding was determined in triplicate by
counting gamma-ray radiation following washing and lysis of cell monolayers. Inter-plate
comparisons were made by counting the number of cells per well in plates prepared in
parallel.
Inositol phosphate assay
Cells were plated into 24-well plates for the 3H-myoinositol assay, performed as described
previously (Morgan et al. 2008 and 2011). Peptide dilutions were prepared in HEPES-
DMEM containing 10 mM LiCl and 0.1% BSA. Receptor stimulation was performed at
37°C for 60 minutes.
Cell growth assay
Cells grown in 12-well plates were treated with GnRH receptor analogues and growth was
analysed by sulforhodamine B staining and spectrophotometric quantification, as described
previously (Morgan et al. 2008, 2011).
Statistical analysis
Analyses of quantitative data were performed using online tools available at http://
easycalculation.com/statistics/standard-deviation.php and http://www.quantitativeskills.com/
sisa/ or using Microsoft Excel (T Test). All data were generated in triplicate on at least two
separate occasions. Graphs were plotted using calculations of mean ± standard error of mean
(SEM) and analyzed by non-linear regression modeling using the Prism software
(GraphPad, USA). T-Test P values < 0.05 were considered to be statistically significant.
Results
All of the GnRH analogues studied exhibited specific binding to the rat GnRH receptor that
was stably expressed in human embryonic kidney cells (HEK293[SCL60]) or immortalized
human prostate epithelial cells (WPE-1-NB26-3) (see Figure 1 and Table 1 for examples).
Displacement of 125I-GnRH bound to the cell surface with different concentrations of
unlabelled GnRH analogues enabled calculation of approximate binding affinities (IC50s,
Table 1).
In HEK293[SCL60] and WPE-1-NB26-3 cells, D-Trp6 GnRH-I exhibited the highest binding
affinity compared to all residue substitution analogues tested. Replacement of Tyr5 by His5
had a modest effect on binding (Table 1). Replacement of Leu7Arg8 by Trp7Tyr8 to generate
‘D-Trp6-GnRH-II’ (His5 D-Trp6Trp7Tyr8 GnRH) resulted in significantly poorer 125I-GnRH
tracer displacement. Differences between binding affinities for certain peptides were
statistically significant (see Figure 1 and Table 1).
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Introduction of a positively charged D-residue side chain at position 6 (D-Lys6 or D-Arg6)
interfered with ligand binding in the D-6 substituted GnRH-I analogues but not in the D-6
substituted GnRH-II analogues (compare results for His5 D-Lys6 GnRH or His5 D-Arg6
GnRH with His5 D-Lys6Trp7Tyr8 GnRH and His5 D-Arg6Trp7Tyr8 GnRH in Table 1).
Comparison of GnRH analogues revealed statistically significant differences in the potency
of agonists to stimulate production of inositol phosphates. D-Trp6 GnRH-I was the most
potent agonist compared to the substitution variants (Figure 2 and Table 1). D-Trp6 GnRH-I
behaved as a super-agonist relative to native GnRH-I at the rat GnRH receptor expressed in
HEK293[SCL60] and WPE-1-NB26-3 cells. Decreased relative potency in the other GnRH
analogues correlated with lower binding affinity.
Dose-response analyses of the effects of GnRH analogues on cell growth were performed
(Figure 3), enabling calculation of IC50s (Table 2). The anti-proliferative potency of GnRH
analogues paralleled binding affinities and EC50s (Tables 1 and 2).
Methyl adducts were incorporated into three separate locations within the benzene ring of
the Trp6 side-chain of DL-Trp6 GnRH-I. These peptides were synthesized as DL epimer
mixtures (50:50% abundance confirmed by HPLC analysis). Each mixture exhibited
differential properties for binding, receptor activation, and inhibition of cell growth (Figure
4 and Table 3).
Methylation at position 5 of the benzene-ring of DL-Trp6 GnRH-I did not adversely affect
the in vitro binding, receptor activation or cell growth inhibitory properties of the peptide
relative to triptorelin (D-Trp6 GnRH-I). Thus 5-methyl-DL-Trp6 GnRH retained high
potency. Methylation at position 4 of the benzene-ring of DL-Trp6 GnRH-I modestly
reduced binding affinity, receptor activation and cell growth inhibitory potency. The IC50
values for binding, EC50 values for receptor activation and IC50 values for growth inhibition
were statistically different relative to D-Trp6 GnRH-I and 5-methyl-DL-Trp6 GnRH using
both cell lines. Methylation at position 6 of the benzene-ring of DL-Trp6 GnRH-I
dramatically reduced binding affinity, receptor activation and cell growth inhibitory
potency. Growth of the prostate cell line was more sensitive to the methyl-DL-Trp6 GnRH
analogues than observed for HEK293[SCL60] cells.
None of the GnRH analogues used in this study exhibited specific binding, inositol
phosphate signalling or significant cell growth inhibition in non-transfected HEK293,
WPE-1-NB26, PC3, LNCaP or DU145 cell lines (data not shown).
Discussion and Conclusions
Using appropriate in vitro tools it has become possible to explore GnRH analog structure-
function relationships with increasing depth and application (Beckers et al. 1995, Coetsee et
al. 2008, Flanagan et al. 1994 and 2000, Fromme et al. 2001, Karten & Rivier 1986, Lopez
de Maturana et al. 2008, Lu et al. 2005 and 2007, Marheineke et al. 1998, Millar & King
1983, Millar et al. 1986, 2004 and 2008, Pfleger et al. 2002 and 2008, Sealfon et al. 1997,
Söderhäll et al. 2005). One challenge is to use this technology to develop GnRH agonists
that are more effective than triptorelin in tumor growth inhibition, ultimately aiming to
enable growth inhibition of cells with moderate to low levels of GnRH receptor or altered
intracellular signalling pathways.
We found that new anti-proliferative agonists may be identified by screening for subtle
changes in GnRH peptide structure which serve to probe the ligand binding site, such as
side-chain alkylation. The latter may result in modified binding and receptor activation
dynamics and altered pharmacodynamics. This approach is distinctly different to the
Morgan et al. Page 4
J Mol Biochem. Author manuscript; available in PMC 2014 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
development of GnRH conjugates containing cleavable toxic adducts (Nagy et al. 2000),
such as GnRH-doxorubicin or GnRH-curcumin (Aggarwal et al. 2011), in which the adduct
moiety is positioned on a linker to avoid contact with the ligand-receptor binding site.
We compared the properties of GnRH analogues containing a D-amino acid residue at
position 6 and combinations of residues found in GnRH-II to the effects of methylation of
residue 6 using two human cell lines expressing high levels of rat GnRH receptor
(HEK293[SCL60] and WPE-1-NB26-3 cells). New insights into GnRH agonist structure-
function were obtained.
Changing the D-amino acid residue at position 6 and the flanking residues at position 5 and
positions 7 and 8 in a range of analogues did not improve binding affinity relative to
triptorelin, (D-Trp6 GnRH-I) (Table 1).
The GnRH-II-like peptides His5D-Arg6Trp7Tyr8-GnRH-I and His5D-Lys6Trp7Tyr8-GnRH-
I, possessed binding affinities similar to D-Trp6 GnRH-I (Table 1). Interestingly, they bind
better than His5D-Trp6Trp7Tyr8-GnRH-I, probably due to the way in which complex charge
and steric interactions between side-chains affect peptide conformation and docking to the
receptor.
Peptide-receptor binding affinity generally correlated with estimates of the EC50 for receptor
activation, although EC50s were poorer than expected (when compared to binding IC50) for
GnRH analogues possessing weaker binding (namely, His5D-Trp6Trp7Tyr8 GnRH, His5D-
Lys6 GnRH and His5D-Arg6 GnRH, Table 1 and Figures 1 and 2). Perhaps analogues with
poor binding affinity are unable to induce the correct receptor conformation for optimal
activation.
We found that the GnRH receptor in the prostate cells appeared to be more efficiently
coupled to inositol phosphate production. This phenomenon may be due to higher receptor
levels, 1.7 fold higher in prostate cells relative to HEK293[SCL60] (Morgan et al. 2011).
Peptide binding and receptor activation relationships were consistent with analyses of cell
growth inhibition (Table 2 and Figure 3), indicating that the level of GnRH receptor
activation correlates with the extent of anti-proliferation in both of these cell types.
Incorporation of D-residues into GnRH-II-like analogues did not enhance binding, receptor
activation or anti-proliferative properties relative to triptorelin (D-Trp6 GnRH-I). Hence our
results negate the hypothesis that GnRH-II agonists may be more effective anti-proliferative
agents than GnRH-I agonists (Lopez de Maturana et al. 2008). Furthermore, corroborative
data generated in the current study indicate that at least two cell models may be required to
properly assess the anti -proliferative properties of GnRH analogues, rather than
examination of HEK293[SCL60] alone, as used previously (Lopez de Maturana et al. 2008).
We note that HEK293[SCL60] cells adhere to matrigel extracellular matrix more efficiently
than to poly-L-lysine coated culture plates. This difference, coupled with the more accurate
sulphorhodamine B growth assay rather than reliance on trypsin/manual cell counting, may
account for inconsistencies between new data and previous studies. It is also possible that
the use of GnRH analogues possessing D-amino acid residues alters the half-life of synthetic
peptides in vitro and that this makes comparisons of anti-proliferative potency with native
GnRH-II-like analogues more difficult to interpret. Further investigations into the in vitro
stability of GnRH analogues are required in this respect.
Since triptorelin was the most potent agonist amongst the substitution ligands studied,
further analyses of the interaction of this peptide with the receptor were performed. The
binding affinity of triptorelin to the rat GnRH receptor is sub-nanomolar, similar to other
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mammalian GnRH receptors (Beckers et al. 1995) although some estimates place it at
around 2 nM (Pfleger et al. 2002 and 2008), probably due to less physiological experimental
conditions (isolated cell membrane suspensions in which structural integrity of receptors is
not biologically maintained by cellular homeostasis). Estimates of GnRH analogue binding
affinity can vary according to the experimental assay and methodology employed. Levels of
GTP and the status of receptor sulfhydryl moieties have been suggested to influence
estimation of GnRH ligand binding affinity (Hazum 1981). Other factors, including the
relative abundance of G proteins and their regulator proteins may conceivably affect the
GnRH receptor conformation through formation of multi-protein macromolecular protein
complexes involving the intracellular face of the receptor.
A modified version of triptorelin, 5-methyl-DL-Trp6 GnRH-I exhibited sub-nanomolar
binding affinity and potency, whereas 6-methyl-DL-Trp6 GnRH-I bound less well to the
receptor and was much less potent (Figure 4 and Table 3). We hypothesise that hydrophobic
and steric constraints conferred by a methyl adduct on the Trp6 benzene ring affect the
opportunities for hydrogen bonding between the Trp6 indole nitrogen atom and the receptor
according to the precise location of the adduct. The methyl moiety in 4- and 6-methyl-DL-
Trp6 GnRH-I may cause steric clash.
These are significant discoveries, building on previous reports documenting the high
potency of isobutyl-naphthyl-alanine at position 6 (Nestor et al. 1982 and 1984). The
possible effects of further methylations of Triptorelin on its pharmacological properties are
intriguing.
Although methyl-DL-Trp6 GnRH-I enantiomeric mixtures were used in our studies (50:50
w/w, confirmed by HPLC-UV detector analysis), it is known that large L-amino acid side
chains are not tolerated at position 6. Substitution of Gly6 with D-Ala6 increased the potency
of the GnRH analog to 350-400% that of native GnRH-I, while a corresponding L-Ala6
substitution resulted in a peptide with a potency of only 4% of native GnRH-I (Karten &
Rivier 1986). As such, we would expect the EC50 of L-Trp6 GnRH-I to have a potency of
only 1% of D-Trp6 GnRH-I and a similar relationship is likely for methyl-L- and methyl-D-
Trp6 GnRH-I analogues, although this remains to be formally confirmed.
Likewise, the relatively bulky L-Asp6 side chain in lamprey GnRH-III results in less than
0.0003% potency relative to mammalian GnRH-I at the human GnRH receptor (Neill 2002)
and Ciona GnRH isoforms possessing an L-amino acid residue at position 6 bind poorly to
mammalian GnRH receptor (Barran et al. 2005). Binding and receptor activation can be
increased ten-fold by substitution with Gly or a D-amino acid at Ciona GnRH position 6
(Barran et al. 2005).
Significantly, since 5-methyl-DL-Trp6 GnRH-I retained properties similar to triptorelin,
further alkylations of the position 6 side chain may be valuable in attempts to improve the
anti-proliferative capacity of GnRH receptor super-agonists. For example, introduction of
hydrophobic moieties may significantly affect the in vivo pharmacodynamics of triptorelin
derivatives. These observations indicate that site-specific ligand methylation/alkylation may
be a superior strategy compared to whole residue substitutions or addition of cleavable
cytotoxic adducts for the identification of new potent anti-proliferative GnRH superagonists
in future studies. Ligand and receptor structure-function studies and molecular modelling are
required to investigate how the methylated triptorelin docks into the agonist binding site in
the GnRH receptor.
Acknowledgments
Thanks to Ronnie Grant for preparing figures and to MRC for funding.
Morgan et al. Page 6
J Mol Biochem. Author manuscript; available in PMC 2014 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
References
Aggarwal S, Ndinguri MW, Solipuram R, Wakamatsu N, Hammer RP, Ingram D, Hansel W.
[DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer
cell growth in vitro and in vivo. Int J Cancer. 2011; 129:1611–1623. [PubMed: 21484797]
Barran PE, Roeske RW, Pawson AJ, Sellar R, Bowers MT, Morgan K, Lu ZL, Tsuda M, Kusakabe T,
Millar RP. Evolution of constrained gonadotropin-releasing hormone ligand conformation and
receptor selectivity. J Biol Chem. 2005; 280:38569–38575. [PubMed: 16157590]
Barron FL, Millar RP, Searle D. Metabolic clearance and plasma half-disappearance time of d-Trp6
and exogenous luteinsing hormone-releasing hormone. Clin Endocr Metab. 1982; 54:1169–1173.
Beckers T, Marheineke K, Reiländer H, Hilgard P. Selection and characterization of mammalian cell
lines with stable over-expression of human pituitary receptors for gonadoliberin. Eur J Biochem.
1995; 231:535–543. [PubMed: 7649152]
Clayton RN, Catt KJ. Receptor-Binding Affinity of Gonadotropin-Releasing Hormone Analogs:
Analysis by Radioligand-Receptor Assay. Endocrinology. 1980; 106:1154–1159. [PubMed:
6244142]
Coetsee M, Millar RP, Flanagan CA, Lu ZL. Identification of Tyr(290(6.58)) of the human
gonadotropin-releasing hormone (GnRH) receptor as a contact residue for both GnRH I and GnRH
II: importance for high-affinity binding and receptor activation. Biochemistry. 2008; 47:10305–
10313. [PubMed: 18771291]
Coy DH, Vilchez-Martinez JA, Coy EJ, Schally AV. Analogs of luteinising hormone releasing
hormone with increased biological activity produced by D-amino acid substitution in position 6. J
Med Chem. 1976; 19:423–425. [PubMed: 1255667]
Deghenghi, R. D-2-alkyl tryptophan compounds. United States Patent 5646301. 1997.
Ezan E, Drieu K, Chapelat M, Rougeot C, Dray F. Radioimmunoassay of [D-Trp6]-luteinizing
hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection
and long-acting formulation administration. Regul Pept. 1986; 14:155–167. [PubMed: 2940625]
Flanagan CA, Becker II, Davidson JS, Wakefield IK, Zhou W, Sealfon SC, Millar RP. Glutamate 301
of the mouse gonadotropin-releasing hormone receptor confers specificity for arginine 8 of
mammalian gonadotropin-releasing hormone. J Biol Chem. 1994; 269:22636–22641. [PubMed:
7915716]
Flanagan CA, Fromme BJ, Davidson JS, Millar RP. A High Affinity Gonadotropin-Releasing
Hormone (GnRH) Tracer, Radioiodinated at Position 6, Facilitates Analysis of Mutant GnRH
Receptors. Endocrinology. 1998; 139:4115–4119. [PubMed: 9751490]
Flanagan CA, Rodic V, Konvicka K, Yuen T, Chi L, Rivier JE, Millar RP, Weinstein H, Sealfon SC.
Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone
receptor contribute differentially to ligand interaction. Biochemistry. 2000; 39:8133–8141.
[PubMed: 10889019]
Franklin J, Hislop J, Flynn A, McArdle CA. Signalling and anti-proliferative effects mediated by
gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using
recombinant adenovirus. J Endocrinol. 2003; 176:275–284. [PubMed: 12553876]
Fromme BJ, Katz AA, Roeske RW, Millar RP, Flanagan CA. Role of aspartate7.32(302) of the human
gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation. Mol
Pharmacol. 2001; 60:1280–1287. [PubMed: 11723235]
Hazum E. Some characteristics of GnRH receptors in rat-pituitary membranes: differences between an
agonist and and antagonist. Mol Cell Endocrinol. 1981; 23:275–281. [PubMed: 6269924]
Ho TL, Nestor JJ Jr, McCrae GI, Vickery BH. Hydrophobic, aza-glycine analogues of luteinizing
hormone-releasing hormone. Int J Pept Protein Res. 1984; 24:79–84. [PubMed: 6384085]
Janáky T, Juhász A, Bajusz S, Csernus V, Srkalovic G, Bokser L, Milovanovic S, Redding TW, Rékási
Z, Nagy A, Schally AV. Analogues of luteinizing hormone releasing hormone containing
cytotoxic groups. Proc Natl Acad Sci U S A. 1992; 89:972–976. [PubMed: 1310542]
Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design: Structure-function studies
toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986;
7:44–66. [PubMed: 2420580]
Morgan et al. Page 7
J Mol Biochem. Author manuscript; available in PMC 2014 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
López de Maturana R, Pawson AJ, Lu ZL, Davidson L, Maudsley S, Morgan K, Langdon SP, Millar
RP. Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of
cell growth: support for the concept of ligand-induced selective signaling. Mol Endocrinol. 2008;
22:1711–1722. [PubMed: 18467526]
Loumaye E, Naor Z, Catt K. Binding affinity and biological activity of gonadotropin-releasing
hormone agonists in isolated pituitary cells. Endocrinology. 1982; 111:730–736. [PubMed:
6286282]
Lu Z-L, Gallagher R, Sellar R, Coetsee M, Millar RP. Mutations remote from the human
gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding
affinity for GnRH II but not GnRH I: evidence for ligand-selective, receptor-active conformations.
J Biol Chem. 2005; 280:29796–29803. [PubMed: 15967801]
Lu ZL, Coetsee M, White CD, Millar RP. Structural determinants for ligand-receptor conformational
selection in a peptide G protein-coupled receptor. J Biol Chem. 2007; 282:17921–17929.
[PubMed: 17452338]
Marheineke K, Lenhard T, Haase W, Beckers T, Michel H, Reiländer H. Characterization of the
human gonadotropin-releasing hormone receptor heterologously produced using the baculovirus/
insect cell and the Semliki Forest virus systems. Cell Mol Neurobiol. 1998; 18:509–524.
[PubMed: 9777251]
Millar RP, King JA. Synthesis and biological activity of [D-Trp6] chicken luteinizing hormone-
releasing hormone. Peptides. 1983; 4:425–429. [PubMed: 6316292]
Millar RP, Milton RC, Follett BK, King JA. Receptor binding and gonadotropin-releasing activity of a
novel chicken gonadotropin-releasing hormone ([His5, Trp7, Tyr8]GnRH) and a D-Arg6 analog.
Endocrinology. 1986; 119:224–231. [PubMed: 3013586]
Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing
hormone receptors. Endocr Rev. 2004; 25:235–275. [PubMed: 15082521]
Millar RP, Pawson AJ, Morgan K, Rissman EF, Lu ZL. Diversity of actions of GnRHs mediated by
ligand-induced selective signaling. Front Neuroendocrinol. 2008; 29:17–35. [PubMed: 17976709]
Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison D, Langdon S,
Millar RP. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell
responses to agonist in vitro and in vivo. Cancer Res. 2008; 68:6331–6340. [PubMed: 18676858]
Morgan K, Stavrou E, Leighton SP, Miller N, Sellar R, Millar RP. Elevated GnRH receptor expression
plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized
human prostate cells. Prostate. 2011; 71:915–928. [PubMed: 21541969]
Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP, Langdon SP.
GnRH receptor activation competes at a low level with growth signaling in stably transfected
human breast cell lines. BMC Cancer. 2011; 11:476. [PubMed: 22051164]
Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone
conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in
vitro: implications for the design of preclinical studies. Proc Natl Acad Sci U S A. 2000; 97:829–
834. [PubMed: 10639165]
Neill JD. Minireview: GnRH and GnRH Receptor Genes in the Human Genome. Endocrinology.
2002; 143:737–743. [PubMed: 11861490]
Nestor JJ Jr, Ho TL, Simpson RA, Horner BL, Jones GH, McCrae GI, Vickery BH. Synthesis and
biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-
releasing hormone. J Med Chem. 1982; 25:795–801. [PubMed: 7050383]
Nestor JJ Jr, Horner BL, Ho TL, Jones GH, McRae GI, Vickery BH. Synthesis of a novel class of
heteroaromatic amino acids and their use in the preparation of analogues of luteinizing hormone-
releasing hormone. J Med Chem. 1984; 27:320–325. [PubMed: 6366232]
Pfleger KD, Bogerd J, Millar RP. Conformational constraint of mammalian, chicken, and salmon
GnRHs, but not GnRH II, enhances binding at mammalian and nonmammalian receptors: evidence
for preconfiguration of GnRH II. Mol Endocrinol. 2002; 16:2155–2162. [PubMed: 12198251]
Pfleger KD, Pawson AJ, Millar RP. Changes to gonadotropin-releasing hormone (GnRH) receptor
extracellular loops differentially affect GnRH analog binding and activation: evidence for distinct
Morgan et al. Page 8
J Mol Biochem. Author manuscript; available in PMC 2014 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
ligand-stabilized receptor conformations. Endocrinology. 2008; 149:3118–3129. [PubMed:
18356273]
Redding TW, Schally AV. Inhibition of prostate tumor growth in two rat models by chronic
administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci
U S A. 1981; 78:6509–6512. [PubMed: 6458815]
Sealfon S, Weinstein H, Millar R. Molecular mechanisms of ligand interaction with the gonadotropin-
releasing hormone receptor. Endocr Rev. 1997; 18:180–205. [PubMed: 9101136]
Söderhäll JA, Polymeropoulos EE, Paulini K, Günther E, Kühne R. Antagonist and agonist binding
models of the human gonadotropin-releasing hormone receptor. Biochem Biophys Res Comm.
2005; 333:568–582. [PubMed: 15950933]
Yabe Y, Miura C, Horikoshi H, Miyagawa H, Baba Y. Synthesis and biological activity of LHRH
analogs substituted by alkyl tryptophans at position 3. Chem Pharm Bul. 1979; 27:1907–1911.
Morgan et al. Page 9
J Mol Biochem. Author manuscript; available in PMC 2014 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1.
A-D. Receptor binding assays for D-6 GnRH analogues. Displacement of 125I-His5D-Tyr6
GnRH-I bound to the surface of cells grown in multi-well plastic culture dishes by co-
incubation with different concentrations of unlabelled GnRH analogue enabled generation of
curves and estimation of relative binding affinities. Examples of binding of four GnRH
ligands to two cell lines expressing rat GnRH receptor are presented. Binding was
determined in triplicate and on separate occasions for each data-point. E-F. Bar charts for
binding IC50 values. Individual IC50 calculations were performed using the Prism software
(Graphpad, USA), assuming a single binding site. The dashed line distinguishes sub-
Morgan et al. Page 10
J Mol Biochem. Author manuscript; available in PMC 2014 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
nanomolar values from nanomolar values. Error bars indicate mean ± SEM, p values derived
using T-test.
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Figure 2.
Inositol phosphate assays. Titrations were performed to enable calculation of EC50s (A-D).
Bar chart representation of receptor activation EC50 values, where dashed lines emphasize
the salient differences between GnRH analogues (E-F). GnRH analogues were screened for
receptor activation using stimulation with a single dose of peptide (10 nM), enabling rapid
comparisons to be made prior to titrations (G-H). Error bars indicate mean ± SEM, p values
derived using T-test.
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Figure 3.
Examples of GnRH analog dose-responses associated with cell growth-inhibition (A-D).
Note that WPE-1-NB26-3 cells grow more slowly than HEK293[SCL60] cells over four days,
hence the difference in the scale bar for optical density at 540 nm (O.D. 540 nm) between
the two cell lines. Values for IC50 calculations are presented as bar graphs (E-G) and dashed
lines emphasise differences in potencies. His5D-Arg6 GnRH exhibited the lowest ability to
inhibit cell growth. Error bars indicate mean ± SEM, p values derived using T-test.
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Figure 4.
Location of methyl-DL-Trp6 side-chain positions 4, 5 and 6 on the benzene ring of the
indole moiety in space-filling depictions of methylated tryptophan.
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Figure 5.
Graphical analyses of binding, receptor activation and cell growth inhibition for methylated
DL-Trp6 GnRH analogues compared to D-Trp6 GnRH-I (A-F; previous page). Bar charts
emphasize differences in affinity and potency for the various analogues (G-M). Error bars
indicate mean ± SEM, p values derived using T-test.
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Table 1
Receptor binding and activation properties of GnRH analogues.
Cell Type HEK293[SCL60] WPE-1-NB26-3
Binding IC50, (nM) Inositol phosphateEC50, (nM) Binding IC50, (nM)
Inositol phosphate
EC50, (nM)
Peptide
D-Trp6 GnRH 0.5 ± 0.2 0.14 ± 0.01 0.9 ± 0.3 0.2 ± 0.03
His5 D-Trp6 GnRH 0.8 ± 0.5 0.6 ± 0.2 0.3 ± 0.1 0.4 ± 0.1
His5 D-Trp6Trp7Tyr8 GnRH 3.4 ± 0.5 5.9 ± 0.9 2.6 ± 0.3 3.9 ± 0.5
His5 D-Lys6 GnRH 3.0 ± 0.5 12.5 ± 1.7 5.1 ± 0.3 6.2 ± 0.2
His5 D-Lys6Trp7Tyr8 GnRH 0.8 ± 0.2 1.7 ± 0.06 0.7 ± 0.2 0.8 ± 0.2
His5 D-Arg6 GnRH 22.3 ± 2.3 45.0 ± 6.9 27.5 ± 4. 9 21.2 ± 6.9
His5 D-Arg6Trp7Tyr8 GnRH 0.5 ± 0.1 1.6 ± 0.2 0.9 ± 0.03 0.9 ± 0.2
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Table 2
Cell growth inhibition potencies of GnRH analogues.
Cell Type HEK293[SCL60] WPE-1-NB26-3
Cell growth inhibition IC50 , (nM) Cell growth inhibition IC50 , (nM)
Peptide
D-Trp6 GnRH 0.4 ± 0.06 0.17 ± 0.05
His5 D-Trp6 GnRH 1.2 ± 0.5 0.4 ± 0.1
His5 D-Trp6Trp7Tyr8 GnRH 0.5 ± 0.06 2.3 ± 0.9
His5 D-Lys6 GnRH 24.8 ± 17.6 3.1 ± 1.8
His5 D-Lys6Trp7Tyr8 GnRH 6.5 ± 2.8 1.1 ± 0.8
His5 D-Arg6 GnRH 35.9 ± 14.8 20.9 ± 11.8
His5 D-Arg6Trp7Tyr8 GnRH 7.5 ± 2.3 0.9 ± 0.4
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Table 3
Receptor binding, activation and cell growth inhibitory properties of methylated triptorelin derivatives.
Cell Type HEK293[SCL60] WPE-1-NB26-3
Binding IC50, (nM) Inositol phosphateEC50, (nM) Binding IC50, (nM)
Inositol phosphate
EC50, (nM)
Peptide
D-Trp6 GnRH 0.5 ± 0.2 0.14 ± 0.01 0.9 ± 0.3 0.15 ± 0.01
6Me DL-Trp6 GnRH 2.3 ± 0.2 1.70 ± 0.4 2.7 ± 0.3 1.05 ± 0.05
5Me DL-Trp6 GnRH 97.7 ± 17.0 0.30 ± 0.03 0.7 ± 0.3 0.17 ± 0.01
4Me DL-Trp6 GnRH 0.6 ± 0.07 36.6 ± 5.10 138.5 ± 26.0 11.90 ±1.40
Cell Type HEK293[SCL60] WPE-1-NB26-3
Cell growth inhibition IC50, (nM ) Cell growth inhibition IC50, (nM)
Peptide
D-Trp6 GnRH 0.4 ± 0.06 0.17 ± 0.05
4Me DL-Trp6 GnRH 4.5 ± 0.6 0.8 ± 0.20
5Me DL-Trp6 GnRH 0.5 ± 0.06 0.1 ± 0.01
6Me DL-Trp6 GnRH 64.4 ± 4.0 10.1 ± 0.10
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